Indian sildenafil brand names occur in international medicine searches, but the name alone does not establish the full composition, origin or U.S. regulatory status of a specific package. Cenforce, Fildena, Kamagra, Suhagra, Caverta and Manforce have product records associated with sildenafil, but their dosage forms, modifiers and company roles differ. For Kamagra, documentation extends beyond internet resale claims: Ajanta Pharma's Philippines website publishes regional prescribing information for sildenafil oral jelly at 50 mg and 100 mg. That is distinct from authentication of any particular sachet or FDA approval in the United States.
This directory provides a comparison framework, not a shopping ranking. Some related product names refer to tablets, oral jelly, soft formulations or combinations with additional active ingredients. A name that begins with a familiar sildenafil brand does not necessarily describe a single-ingredient sildenafil tablet. Likewise, a tablet sold in India is not automatically equivalent to an FDA-approved generic sildenafil ED tablet.
For U.S. prescriptions, use the FDA-approved generic sildenafil guide and lawful pharmacy-access overview. The brand pages linked below focus on identity and provenance, not promises of international delivery or personal importation.
Every brand entry should distinguish the reported product name, active ingredient, dosage form, strength if reliably labeled, the company listed on the pack, that company’s role and its intended market. When primary evidence is absent or inconsistent, the correct description is a documented claim or unresolved detail rather than a definitive current product listing.
Regulatory status is a separate column of analysis. A foreign company may operate in regulated markets, but an India-market brand is not assumed to have an FDA-approved U.S. application merely because a firm’s name is recognizable.
The names below lead to individual editorial checks rather than sales pages. Each page addresses a different mix of reported company relationships and product-family complexity. The entries should be read with the exact package and current documentation in mind, not treated as an exhaustive inventory.
Products with suffixes such as “Force,” “Super,” “Soft” or “Oral Jelly” require their own ingredient and dosage-form checks. There is no basis for combining those listings into one interchangeable product group.
| Brand guide | Reported brand context | Key identity check |
|---|---|---|
| Cenforce | Centurion-linked sildenafil tablet listings | Distinguish basic tablets from other forms and variants |
| Fildena | Fortune Healthcare-linked sildenafil listings | Confirm forms, variant names and listed company role |
| Kamagra | Ajanta-linked sildenafil tablet record; company Philippines website also documents 50 mg and 100 mg oral jelly | Separate verified regional jelly labeling from India-market tablets and unauthenticated seller stock |
| Suhagra | Cipla-associated sildenafil tablets | Do not merge with Suhagra Force combination claims |
| Caverta | Sun Pharma India sildenafil product listing | Confirm product form and market-specific label |
| Manforce | Mankind-associated sildenafil tablet name | Separate condoms and differently formulated brand extensions |
Cenforce is associated with Centurion Laboratories listings that describe sildenafil tablets and other presentations. Product pages and resellers may disagree on descriptions, strengths or packaging, so a single Cenforce claim is not sufficient to identify a particular item.
Fildena appears in Fortune Healthcare-linked listings that also mention a range of forms and variant names. Read the Cenforce guide and the Fildena guide for their separate company and product checks rather than generalizing from the shared sildenafil ingredient.
Kamagra has separately documented product forms. An Indian pharmacy listing identifies a Kamagra 100 mg sildenafil tablet and Ajanta Pharma as marketer. Ajanta Pharma Philippines additionally publishes its own product information for Kamagra sildenafil oral jelly, listing 50 mg and 100 mg sachet presentations. These are concrete but market-specific records, not merely internet sellers repeating one another. A regional company product page does not authenticate every package advertised internationally.
Tablet and oral-jelly presentations must be evaluated as different formulations, and neither regional record proves an FDA-approved U.S. Kamagra application or therapeutic equivalence to Viagra tablets. The Kamagra brand dossier explains the evidence tiers, composition and U.S. approval boundary. Do not interpret flavor, dose or a company logo as a substitute for legitimate U.S. dispensing.
Suhagra is associated with Cipla and sildenafil tablets in Indian product information. A related name such as Suhagra Force can refer to a different or combined formulation, and must never be assumed to contain only sildenafil based on the parent brand.
Caverta is included in Sun Pharma’s Indian product catalog as a sildenafil tablet product. Read the Suhagra guide and the Caverta guide for product-specific identity rather than generic assumptions about the companies’ entire portfolios.
Manforce is a particularly ambiguous search term: the name is also associated with a consumer condom brand, and similarly named medicines may have different ingredients. Super Manforce listings in Indian retail sources are inconsistent with simple assumptions about sildenafil-only tablets.
The Manforce product guide asks readers to verify the exact active ingredient and formulation shown on the specific medicine pack, rather than classifying all results as interchangeable sildenafil prescriptions.
FDA approval in the United States is product- and application-specific. Sharing sildenafil as an ingredient is not sufficient to establish an approved application, therapeutic-equivalence rating or lawful U.S. market status for an imported brand.
The FDA has separate requirements for drug importation; routine internet ordering of a foreign unapproved brand should not be presented as a standard U.S. prescription route. The U.S. generic guide explains the approved category without confusing it with international brands.
A manufacturer may produce finished tablets while another entity markets them or distributes the packs. Third-party exporters may show a recognizable brand beside their own contact details. Those listings do not prove the exporter owns the brand or that all advertised variants originate from the same manufacturing site.
The manufacturer-records guide explains how to interpret applicant, labeler, manufacturing and distribution roles using U.S. product records; similar precision is useful when reading Indian packaging claims.
The addition of another active ingredient changes the product identity, potential harms and therapeutic claim. Terms such as “combination,” “Force,” or different marketed product suffixes are cues to inspect ingredients; they are not evidence of a standard approved ED-tablet equivalent.
If the ingredient list cannot be established from reliable current documentation, the correct editorial outcome is to withhold a precise claim. An unverified oral-jelly or soft-gel listing should not be presented as an FDA-approved dosage form for U.S. ED use.
When researching a named foreign product, compare its full name, dosage form, labeled active ingredients, strength, batch and manufacturer or marketer details across credible product documentation. Note the market where the product is listed. A promotional image or reseller description is not enough to establish approval or authenticity.
U.S. readers evaluating ED therapy should discuss appropriately prescribed options with a clinician and use a licensed U.S. pharmacy. The sildenafil hub and ED medication directory provide the broader clinical and product overview.
No. Some listings share sildenafil as an ingredient, but identity, dosage form, other ingredients and regulatory authorization must be assessed per product.
U.S. FDA approval cannot be inferred from their names or sildenafil ingredient. Check the exact product and approved application.
No. Ajanta Pharma Philippines documents regional Kamagra oral-jelly products containing sildenafil, but that does not make them FDA-approved U.S. sildenafil tablets or establish equivalence, import eligibility or the authenticity of a specific online seller.
Related brand names may indicate different ingredient combinations; the actual label must be checked.
Sun Pharma lists Caverta as a sildenafil tablet in its India-market product portfolio; that does not by itself establish a U.S. FDA-approved Caverta product.
No. The brand name can refer to different product categories, and similarly named medicines may contain different ingredients.
Importing unapproved prescription drugs is generally unlawful in the U.S.; specific FDA policy exceptions are limited and not standard retail pathways.
Use a clinician-issued prescription and verify the exact FDA-approved medication dispensed by a licensed U.S. pharmacy.